Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review

被引：107
作者：
Zhao, Liang [1 ,2 ,3 ]
Chen, Jianhao [3 ]
Pang, Yizhen [1 ,2 ]
Fu, Kaili [4 ]
Shang, Qihang [1 ,2 ]
Wu, Hua [1 ,2 ]
Sun, Long [1 ,2 ]
Lin, Qin [3 ]
Chen, Haojun [1 ,2 ]
机构：
[1] Xiamen Univ, Dept Nucl Med, Affiliated Hosp 1, Xiamen, Peoples R China
[2] Xiamen Univ, Minnan PET Ctr, Affiliated Hosp 1, Xiamen, Peoples R China
[3] Xiamen Univ, Dept Radiat Oncol, Affiliated Hosp 1, Xiamen, Peoples R China
[4] Jiaxing Univ, Dept Oncol, Affiliated Hosp 2, Jiaxing, Peoples R China
来源：
THERANOSTICS | 2022年 / 12卷 / 04期
基金：
中国国家自然科学基金;
关键词：
cancer-associated fibroblasts (CAF); fibroblast activation protein (FAP); targeted radionuclide therapy; PET; CT; cancer management; VOLUME DELINEATION; FAP; THERAPY; EXPRESSION; EXPERIENCE; INHIBITOR; CARCINOMA; F-18-FDG; PATIENT; BREAST;
D O I：
10.7150/thno.69475
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
In recent years, quinoline-based fibroblast activation protein (FAP) inhibitors (FAPI) have shown promising results in the diagnosis of cancer and several other diseases, making them the hotspot of much productive research. This review summarizes the literature for the state-of-the-art FAPI-PET imaging for cancer diagnosis compared with fluorodeoxyglucose (FDG)-PET. We also summarize the use of FAPI-PET for therapeutic regimen improvement and fibroblast activation protein (FAP)-targeted molecule modification strategies, as well as preliminary clinical studies regarding FAP-targeted radionuclide therapy. Our qualitative summary of the literature to date can inform future research directions, medical guidelines, and optimal clinical decision-making.
引用
收藏
页码：1557 / 1569
页数：13
相关论文
共 86 条
  • [1] Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients With Relapsed or Refractory Cancers A Preliminary Study
    Assadi, Majid
    Rekabpour, Seyed Javad
    Jafari, Esmail
    Divband, GhasemAli
    Nikkholgh, Babak
    Amini, Hamidreza
    Kamali, Hassan
    Ebrahimi, Sakineh
    Shakibazad, Nader
    Jokar, Narges
    Nabipour, Iraj
    Ahmadzadehfar, Hojjat
    [J]. CLINICAL NUCLEAR MEDICINE, 2021, 46 (11) : E523 - E530
  • [2] The angiogenic switch in carcinogenesis
    Baeriswyl, Vanessa
    Christofori, Gerhard
    [J]. SEMINARS IN CANCER BIOLOGY, 2009, 19 (05) : 329 - 337
  • [3] Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study
    Ballal, Sanjana
    Yadav, Madhav Prasad
    Moon, Euy Sung
    Roesch, Frank
    Kumari, Samta
    Agarwal, Shipra
    Tripathi, Madhavi
    Sahoo, Ranjit Kumar
    Mangu, Bharadwaj Srinivas
    Tupalli, Avinash
    Bal, Chandrasekhar
    [J]. THYROID, 2022, 32 (01) : 65 - 77
  • [4] A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy
    Ballal, Sanjana
    Yadav, Madhav Prasad
    Kramer, Vasko
    Moon, Euy Sung
    Roesch, Frank
    Tripathi, Madhav
    Mallick, Soumyaranjan
    ArunRaj, Sreedharan Thankarajan
    Bal, Chandrasekhar
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (03) : 942 - 944
  • [5] Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results
    Baum, Richard P.
    Schuchardt, Christiane
    Singh, Aviral
    Chantadisai, Maythinee
    Robiller, Franz C.
    Zhang, Jingjing
    Mueller, Dirk
    Eismant, Alexander
    Almaguel, Frankis
    Zboralski, Dirk
    Osterkamp, Frank
    Hoehne, Aileen
    Reineke, Ulrich
    Smerling, Christiane
    Kulkarni, Harshad R.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (03) : 415 - 423
  • [6] Bergmann C, LANCET RHEUMATOL, V3, pe185
  • [7] FAP: The Next Billion Dollar Nuclear Theranostics Target?
    Calais, Jeremie
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (02) : 163 - 165
  • [8] 18F-FDG and 68Ga-FAPI PET/CT in the Evaluation of Ground-Glass Opacity Nodule
    Chen, Haojun
    Pang, Yizhen
    Meng, Tinghua
    Yu, Xiuyi
    Sun, Long
    [J]. CLINICAL NUCLEAR MEDICINE, 2021, 46 (05) : 424 - 426
  • [9] Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings
    Chen, Haojun
    Zhao, Liang
    Ruan, Dan
    Pang, Yizhen
    Hao, Bing
    Dai, Yaqing
    Wu, Xiurong
    Guo, Wei
    Fan, Chunlei
    Wu, Jingxun
    Huang, Weipeng
    Lin, Qin
    Sun, Long
    Wu, Hua
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (01) : 73 - 86
  • [10] Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer
    Chen, Haojun
    Pang, Yizhen
    Wu, Jingxun
    Zhao, Liang
    Hao, Bing
    Wu, Jing
    Wei, Jihong
    Wu, Siming
    Zhao, Long
    Luo, Zuoming
    Lin, Xuehua
    Xie, Chengrong
    Sun, Long
    Lin, Qin
    Wu, Hua
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (08) : 1820 - 1832
123456789